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More Data, No Answers*Matthew R. Reynolds, MD, MSCyzSEE PAGE 660D espite—or perhaps because of—a very longhistory of clinical use, high-quality evi-dence regarding the long-term clinical
outcomes with digoxin and related cardiac glycosides
is limited. It took until the late 1990s to complete a
large randomized trial that clariﬁed digoxin’s role in
the treatment of heart failure (HF) (decreased hospi-
talization, no effect on mortality) (1). With respect
to atrial ﬁbrillation (AF), digoxin’s other main thera-
peutic target, no such randomized outcomes trial
has ever been completed. As a result, the best avail-
able evidence on clinical outcomes with digoxin in
AF patients comes from post-hoc analyses of clinical
trials designed to answer other questions, or from
observational studies.
Patients treated with digoxin tend to be older and
sicker than those not treated with digoxin (2). In
several studies, digoxin treatment in AF patients has
been associated with increased crude mortality rates,
raising the question: Is it the patients, or the drug?
The key to answering this question lies in fully
accounting for the differences between the patients
who do and do not receive the drug. There are
different ways to adjust for such differences in
observational research. However, even when similar
analysis methods are used, data elements can vary
depending on data sources. Even “exposure” to a
drug can be deﬁned in more than 1 way. It should not
come as a surprise then, that previous studies of this
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regarding a possible link between digoxin and
mortality in AF patients after adjustment for con-
founding factors, one reporting an association (2), the
other ﬁnding none (3). Likewise, 2 simultaneously
published post-hoc analyses of the AFFIRM (Atrial
Fibrillation Follow-Up Investigation of Rhythm
Management) trial, using different analytic methods,
reported opposite conclusions as to whether or not
digoxin increases mortality (4,5).
Into this fray enters a new analysis of outcomes in
AF patients treated with digoxin, based on a large
national sample of patients treated in the Veteran’s
Administration (VA) health system (6). In a program
called TREAT-AF (The Retrospective Evaluation and
Assessment of Therapies in AF), Turakhia et al. (6), in
this issue of the Journal, using novel linkages
between clinical, pharmacy, claims, and mortality
databases, have assembled a cohort of more than
120,000 veterans with incident AF between 2004 and
2008. This unique database was used to explore the
potential association between digoxin use and mor-
tality over a roughly 3-year period.A remarkable 23% of the study cohort was pre-
scribed digoxin within 90 days of the ﬁrst AF
encounter, with <25% of them carrying a diagnosis of
HF. The investigators found the expected crude
relationship between digoxin use and mortality with
an unadjusted hazard ratio (HR) of w1.37. The
strength of this association was attenuated in multi-
variable Cox models both in the full study population
(HR: 1.26) and in a propensity-matched subset that
included 93% of the digoxin-treated patients (HR:
1.21). The investigators additionally provided a
sensitivity analysis in which the prevalence of a
potential confounder that would obviate their results
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tion between that confounder and mortality.
This new, well-conducted study has several
notable strengths. The sample size is at least 20 times
larger than any prior study on the topic, the sample is
drawn from many clinical centers around the United
States, and the time frame of observation is more
contemporary than some previous studies (e.g., the
AFFIRM trial). The source data may therefore be more
representative of current U.S. practice than that of
previous analyses. State-of-the-art methods for
observational research were used, within the con-
straints of the available data. The sensitivity analysis
suggests that the main study ﬁnding may be difﬁcult
to ascribe to a single unmeasured confounder.
A few important limitations of the study also
require discussion. Studies that are based on VA
populations underrepresent women, an issue that
matters in this case as a post-hoc analysis of the DIG
(Digitalis Investigation Group) trial showed an
important interaction between sex and outcomes in
patients with HF (7). However, in that study, the risk
was higher in women than in men. The investigators
did not have information on digoxin doses or serum
digoxin levels, but were able to calculate estimated
glomerular ﬁltration rate and did not ﬁnd any dif-
ference across glomerular ﬁltration rate strata.
More importantly, ﬁndings from observational
studies always suffer from the reality that treatment
decisions in medicine are nonrandom and frequently
made on the basis of factors that cannot be measured,
and therefore cannot be used in multivariable
adjustment models or propensity score calculations.
Findings from observational studies must therefore
always be interpreted with caution. For example, a
recent Swedish observational study reported that
patients with AF and HF who were treated with dro-
nedarone had lower mortality than AF patients with
HF who did not receive dronedarone (8). Given pre-
vious clinical trial evidence (9), it would be erroneous
to conclude that dronedarone reduces mortality in HF
patients—rather, it must be the case that, in accor-
dance with recommendations, dronedarone is selec-
tively used in lower-risk HF patients.
In the case of the study from Turakhia et al. (6), the
investigators did not have access to data on left ven-
tricular ejection fraction or New York Heart Associa-
tion functional class, and therefore, they could notadjust for HF severity. Given its accepted role in the
treatment of HF, it seems likely that digoxin is selec-
tively used in higher-risk patients, and that these and
possibly other unmeasured factors could mediate the
reported relationship between digoxin and mortality,
such that the “true” hazard ratio is likely to be less than
the reported w1.2. How close to unity is the “true”
hazard ratio? The only way to know for sure is to test
the hypothesis in a randomized trial.
What should clinicians do with this (and other
recent) data regarding possible riskswith digoxin in AF
patients? It has been realized for some time that
digoxin is no longer the ﬁrst choice for rate control in
AF patients, because other drugs are both safer
and more effective. It is now widely recognized
that digoxin exerts its rate-controlling effects via
enhancement of vagal tone, a mechanism that is easily
overcome by exercise and other high catecholamine
states (10). It has also long been known that digoxin
has a narrow therapeutic window, and that adverse
effects, including mortality, are related to higher
serum levels (11). Safety continues to be an issue: more
patients are hospitalized for adverse effects from
digoxin than for any cardiovascular medicine other
than antiplatelet and anticoagulant drugs (12). If
digoxin is to be used, it is clear that dosing should
be conservative, particularly in the elderly.
The main implication of the Turakhia et al. (6) paper
and related data is that digoxin should be used
selectively and with care in AF patients. This view is
reﬂected in the recently updated AF treatment guide-
lines, where beta-blockers and non-dihydropyridine
calcium channel blockers were given a Class I recom-
mendation for rate control, and digoxin received no
speciﬁc recommendation at all (13).
Should the use of digoxin for rate control in AF be
abandoned altogether? Such a recommendation
cannot be made on the basis of this kind of observa-
tional data. Going forward, the role of digoxin in AF
treatment may continue to diminish. For now, there
are still clinical circumstances (HF, difﬁcult rate
control, low blood pressure) where this old herbal
remedy remains useful.
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